Mood, Anxiety and Olfactory Dysfunction in COVID-19: Evidence of Central Nervous System Involvement?

Marlene M Speth, Thirza Singer-Cornelius, Michael Oberle, Isabelle Gengler, Steffi J Brockmeier, Ahmad R Sedaghat, Marlene M Speth, Thirza Singer-Cornelius, Michael Oberle, Isabelle Gengler, Steffi J Brockmeier, Ahmad R Sedaghat

Abstract

Objective: The objective of this study was to determine the burden of depressed mood and anxiety in COVID-19, and associated disease characteristics.

Materials and methods: This is a prospective, cross-sectional study of 114 COVID-19 positive patients diagnosed using RT-PCR-based testing over a 6-week period. The two-item Patient Health Questionnaire (PHQ-2) and the two-item Generalized Anxiety Disorder questionnaire (GAD-2) were used to measure depressed mood and anxiety level, respectively, at enrollment and for participants' baseline, pre-COVID-19 state. Severity of smell loss, loss of taste, nasal obstruction, rhinorrhea/mucus production, fever, cough, and shortness of breath (SOB) during COVID-19 were assessed.

Results: PHQ-2 and GAD-2 significantly (P < .001) increased from baseline to enrollment. PHQ-2 was associated with smell loss (adjusted incidence rate ratio [aIRR] = 1.40, 95% CI, 1.10-1.78, P = .006), age (aIRR = 1.02, 95% CI, 1.01-1.04, P = .006), and baseline PHQ-2 score (aIRR = 1.39, 95% CI, 1.09-1.76, P = .007). GAD-2 score was associated with smell loss (aIRR = 1.29, 95% CI, 1.02-1.62, P = .035), age (aIRR = 1.02, 95% CI, 1.01-1.04, P = .025) and baseline GAD-2 score (aIRR = 1.55, 95% CI, 1.24-1.93, P < .001). Loss of taste also exhibited similar associations with PHQ-2 and GAD-2. PHQ-2 and GAD-2 scores were not associated with severities of any other symptoms during the COVID-19 course.

Conclusions: Despite the occurrence of symptoms-such as SOB-associated with severe manifestations of COVID-19, only the severities of smell and taste loss were associated with depressed mood and anxiety. These results may raise the novel possibility of emotional disturbance as a CNS manifestation of COVID-19 given trans-olfactory tract penetration of the central nervous system (CNS) by coronaviruses.

Level of evidence: 3 Laryngoscope, 130:2520-2525, 2020.

Keywords: Coronavirus, COVID-19, SARS-CoV2, SARS-CoV-2, mood, depression, anxiety, anosmia, hyposmia, olfactory dysfunction, olfactory function, gustatory dysfunction, gustatory function, olfaction, smell, taste, nasal obstruction, rhinorrhea.

© 2020 American Laryngological, Rhinological and Otological Society Inc, "The Triological Society" and American Laryngological Association (ALA).

Figures

Fig. 1
Fig. 1
The baseline (pre‐COVID‐19) and COVID‐19 (time of enrollment) PHQ‐2 and GAD‐2 scores of participants connected by a line segment. GAD‐2 = Generalized Anxiety Disorder Questionnaire; PHQ‐2 = two‐item Patient Health Questionnaire
Fig. 2
Fig. 2
Scatter plots of PHQ‐2 score and GAD‐2 score versus severity of decreased sense of smell at enrollment, with data marker size coded by baseline PHQ‐2 or GAD‐2 score (respectively) and color coded by age. GAD‐2 = Generalized Anxiety Disorder Questionnaire; PHQ‐2 = two‐item Patient Health Questionnaire

References

    1. Wu D, Wu T, Liu Q, Yang Z. The SARS‐CoV‐2 outbreak: what we know. Int J Infect Dis 2020;94:44–48.
    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.
    1. Mahase E. Covid‐19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. BMJ 2020;368:m1036.
    1. Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID‐19 in Europe: a case series. Lancet Infect Dis 2020;20:697–706.
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–513.
    1. Sedaghat AR, Gengler I, Speth MM. Olfactory dysfunction: a highly prevalent symptom of COVID‐19 with public health significance. Otolaryngol Head Neck Surg 2020;163:12–15.
    1. Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with cancer. BMJ 2018;361:k1415.
    1. Murphy B, Le Grande M, Alvarenga M, Worcester M, Jackson A. Anxiety and depression after a cardiac event: prevalence and predictors. Front Psychol 2019;10:3010.
    1. Badescu SV, Tataru C, Kobylinska L, et al. The association between diabetes mellitus and depression. J Med Life 2016;9:120–125.
    1. Huang Y, Zhao N. Generalized anxiety disorder, depressive symptoms and sleep quality during COVID‐19 outbreak in China: a web‐based cross‐sectional survey. Psychiatry Res 2020;288:112954.
    1. Sonderskov KM, Dinesen PT, Santini ZI, Ostergaard SD. The depressive state of Denmark during the COVID‐19 pandemic. Acta Neuropsychiatr 2020;32:226–228.
    1. Rajkumar RP. COVID‐19 and mental health: a review of the existing literature. Asian J Psychiatr 2020;52:102066.
    1. Wang C, Pan R, Wan X, et al. A longitudinal study on the mental health of general population during the COVID‐19 epidemic in China. Brain Behav Immun 2020;87:40–48.
    1. Neto MLR, Almeida HG, Esmeraldo JD, et al. When health professionals look death in the eye: the mental health of professionals who deal daily with the 2019 coronavirus outbreak. Psychiatry Res 2020;288:112972.
    1. Xu J, Xu QH, Wang CM, Wang J. Psychological status of surgical staff during the COVID‐19 outbreak. Psychiatry Res 2020;288:112955.
    1. Yuan R, Xu QH, Xia CC, et al. Psychological status of parents of hospitalized children during the COVID‐19 epidemic in China. Psychiatry Res 2020;288:112953.
    1. Xiao H, Zhang Y, Kong D, Li S, Yang N. Social capital and sleep quality in individuals who self‐isolated for 14 days during the coronavirus disease 2019 (COVID‐19) outbreak in January 2020 in China. Med Sci Monit 2020;26:e923921.
    1. DePierro J, Lowe S, Katz C. Lessons learned from 9/11: mental health perspectives on the COVID‐19 pandemic. Psychiatry Res 2020;288:113024.
    1. Speth MM, Singer‐Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat AR. Olfactory dysfunction and sinonasal symptomatology in COVID‐19: prevalence, severity, timing and associated characteristics. Otolaryngol Head Neck Surg 2020;163:114–120.
    1. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire‐2: validity of a two‐item depression screener. Med Care 2003;41:1284–1292.
    1. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD‐7. Arch Intern Med 2006;166:1092–1097.
    1. Linder A. Symptom scores as measures of the severity of rhinitis. Clin Allergy 1988;18:29–37.
    1. Spence C. Multisensory flavor perception. Cell 2015;161:24–35.
    1. Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID‐19)‐an emerging global health threat. J Infect Public Health 2020;13:644–646.
    1. Omer SB, Malani P, Del Rio C. The COVID‐19 pandemic in the US: a clinical update. JAMA 2020. 10.1001/jama.2020.5788.
    1. Gengler I, Wang JC, Speth MM, Sedaghat AR. Sinonasal pathophysiology of SARS‐CoV‐2 and COVID‐19: a systematic review of the current evidence. Laryngoscope Investig Otolaryngol 2020;5:354–359.
    1. Rodriguez‐Morales AJ, Rodriguez‐Morales AG, Mendez CA, Hernandez‐Botero S. Tracing new clinical manifestations in patients with COVID‐19 in Chile and its potential relationship with the SARS‐CoV‐2 divergence. Curr Trop Med Rep 2020;13:644–646.
    1. Lechien JR, Chiesa‐Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild‐to‐moderate forms of the coronavirus disease (COVID‐19): a multicenter European study. Eur Arch Otorhinolaryngol 2020;277:2251–2261.
    1. Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS. Association of chemosensory dysfunction and Covid‐19 in patients presenting with influenza‐like symptoms. Int Forum Allergy Rhinol 2020;10:806–813.
    1. Erskine SE, Philpott CM. An unmet need: patients with smell and taste disorders. Clin Otolaryngol 2020;45:197–203.
    1. Hur K, Choi JS, Zheng M, Shen J, Wrobel B. Association of alterations in smell and taste with depression in older adults. Laryngoscope Investig Otolaryngol 2018;3:94–99.
    1. Siopi E, Denizet M, Gabellec MM, et al. Anxiety‐ and depression‐like states Lead to pronounced olfactory deficits and impaired adult neurogenesis in mice. J Neurosci 2016;36:518–531.
    1. McCray PB Jr, Pewe L, Wohlford‐Lenane C, et al. Lethal infection of K18‐hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol 2007;81:813–821.
    1. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol 2008;82:7264–7275.
    1. Asadi‐Pooya AA, Simani L. Central nervous system manifestations of COVID‐19: a systematic review. J Neurol Sci 2020;413:116832.
    1. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS‐CoV‐2 infection. N Engl J Med 2020;382:2268–2270.
    1. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients. J Med Virol 2020;92:552–555.
    1. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS‐Coronavirus‐2. Int J Infect Dis 2020;94:55–58.
    1. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID‐19 virus targeting the CNS: tissue distribution, host‐virus interaction, and proposed neurotropic mechanisms. ACS Chem Nerosci 2020;11:995–998.
    1. Bhandari A, Wagner T. Self‐reported utilization of health care services: improving measurement and accuracy. Med Care Res Rev 2006;63:217–235.
    1. Neugebauer R, Ng S. Differential recall as a source of bias in epidemiologic research. J Clin Epidemiol 1990;43:1337–1341.
    1. Schmier JK, Halpern MT. Patient recall and recall bias of health state and health status. Expert Rev Pharmacoecon Outcomes Res 2004;4:159–163.
    1. Norquist JM, Girman C, Fehnel S, DeMuro‐Mercon C, Santanello N. Choice of recall period for patient‐reported outcome (PRO) measures: criteria for consideration. Qual Life Res 2012;21:1013–1020.
    1. Moein ST, Hashemian SMR, Mansourafshar B, Khorram‐Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID‐19. Int Forum Allergy Rhinol 2020;10:944–950.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren